英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
parricus查看　parricus　在百度字典中的解释百度英翻中〔查看〕
parricus查看　parricus　在Google字典中的解释Google英翻中〔查看〕
parricus查看　parricus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Arrowhead Pharmaceuticals Home | Arrowhead . . .
    Changing the way diseases are treated, Arrowhead pharmaceuticals uses innovative, scientific methods to discover, develop, and deliver therapies and solutions
  • Investors | Arrowhead Pharmaceuticals Inc.
    The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc 's business for stockholders, potential investors, and financial analysts
  • Science Innovation | Arrowhead Pharmaceuticals, Inc.
    The Arrowhead TRiM™ platform is a robust and versatile drug discovery and development platform It has broad freedom to operate and utilizes a toolbox of RNAi delivery technologies, chemistries, structures and manufacturing techniques After more than a decade working on RNA interference (RNAi)-based therapies, this platform enables us to develop new therapies faster, more cost effectively
  • Our Pipeline | Arrowhead Pharmaceuticals, Inc.
    Check out the development of Arrowhead’s products to treat challenging cardiometabolic, pulmonary, neuromuscular, liver, and more types of diseases
  • Arrowhead Pharmaceuticals 2026 First Quarter Results . . .
    The Investor Relations website contains information about Arrowhead Pharmaceuticals Inc 's business for stockholders, potential investors, and financial analysts
  • About Us | Arrowhead Pharmaceuticals, Inc.
    Learn more about Arrowhead Pharmaceutical's foundation as a therapeutic discovery company, innovative use of RNAi, and ambitious pipeline for developing medicines
  • Newsroom | Arrowhead Pharmaceuticals, Inc.
    Stay up to date on Arrowhead Pharmaceutical's latest news, stories, and events Read about recent studies on potential treatments, healthcare conferences, and more!
  • Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End . . .
    “Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology We have the potential to impact the lives of millions of patients in need We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, more
  • Arrowhead Subsidiary Visirna Sells Rights to . . .
    Arrowhead is further eligible to receive royalties on net commercial product sales in Greater China as part of the Arrowhead-Visirna license which was assigned in part to Sanofi Gibson, Dunn Crutcher LLP and Sidley Austin LLP are serving as legal advisors to Arrowhead
  • Arrowhead Pharmaceuticals Announces Closing of Global . . .
    Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27 25 per share Arrowhead will also receive $250 million to be paid in annual installments of $50 million over 5 years Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of





中文字典-英文字典  2005-2009